Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study
- PMID: 22237833
- PMCID: PMC6342466
- DOI: 10.1002/mds.24892
Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study
Abstract
To test the association between impaired olfaction and other prodromal features of PD in the Parkinson At-Risk Syndrome Study. The onset of olfactory dysfunction in PD typically precedes motor features, suggesting that olfactory testing could be used as a screening test. A combined strategy that uses other prodromal nonmotor features, along with olfactory testing, may be more efficient than hyposmia alone for detecting the risk of PD. Individuals with no neurological diagnosis completed a mail survey, including the 40-item University of Pennsylvania Smell Identification Test, and questions on prodromal features of PD. The frequency of reported nonmotor features was compared across individuals with and without hyposmia. A total of 4,999 subjects completed and returned the survey and smell test. Of these, 669 were at or below the 15th percentile based on age and gender, indicating hyposmia. Hyposmics were significantly more likely to endorse nonmotor features, including anxiety and depression, constipation, and rapid eye movement sleep behavior disorder symptoms, and to report changes in motor function. Twenty-six percent of subjects with combinations of four or more nonmotor features were hyposmic, compared to 12% for those reporting three or fewer nonmotor features (P < 0.0001). Hyposmia is associated with other nonmotor features of PD in undiagnosed individuals. Further assessment of hyposmic subjects using more specific markers for degeneration, such as dopamine transporter imaging, will evaluate whether combining hyposmia and other nonmotor features is useful in assessing the risk of future neurodegeneration.
Copyright © 2012 Movement Disorder Society.
Figures


References
-
- Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord 2001;16:1023–1032. - PubMed
-
- Gonera EG, Van’t Hof M, Berger HJC, Van Weel C, Horstink WIM. Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 1997;12:871–876. - PubMed
-
- Stern MB. The preclinical detection of Parkinson’s disease: ready for prime time? Ann Neurol 2004;56:169–171. - PubMed
-
- Stern MB, Doty RL, Dotti M, et al. Olfactory function in Parkinson’s disease subtypes. Neurology 1994;44:266–268. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical